A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data by 정현철 & 조재용
Vol:.(1234567890)




A phase 3 study of nivolumab in previously treated advanced gastric 
or gastroesophageal junction cancer (ATT RAC TION‑2): 2‑year update 
data
Li‑Tzong Chen1,2 · Taroh Satoh3 · Min‑Hee Ryu4 · Yee Chao5 · Ken Kato6 · Hyun Cheol Chung7 · Jen‑Shi Chen8 · 
Kei Muro9 · Won Ki Kang10 · Kun‑Huei Yeh11,12 · Takaki Yoshikawa13,26 · Sang Cheul Oh14 · Li‑Yuan Bai15 · 
Takao Tamura16,27 · Keun‑Wook Lee17 · Yasuo Hamamoto18 · Jong Gwang Kim19 · Keisho Chin20 · Do‑Youn Oh21 · 
Keiko Minashi22 · Jae Yong Cho23 · Masahiro Tsuda24 · Hiroki Sameshima25 · Yoon‑Koo Kang4 · Narikazu Boku6
Received: 16 September 2019 / Accepted: 10 December 2019 / Published online: 20 December 2019 
© The Author(s) 2019
Abstract
Background Nivolumab showed improvement in overall survival (OS) in ATT RAC TION-2, the first phase 3 study in patients 
with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year follow-up results 
of ATT RAC TION-2 are presented herein.
Methods ATT RAC TION-2 was a randomized, double-blind, placebo-controlled, phase 3 trial (49 sites; Japan, South Korea, 
and Taiwan). The median (min–max) follow-up period was 27.3 (24.1–36.3) months. The primary endpoint was OS. A suba-
nalysis of OS was performed based on best overall response and tumor-programmed death ligand-1 (PD-L1) expression status.
Results Overall, 493 of 601 screened patients were randomized (2:1) to receive nivolumab (330) or placebo (163). OS 
(median [95% confidence interval; CI]) was significantly longer in the nivolumab group (5.26 [4.60–6.37] vs 4.14 [3.42–
4.86] months in placebo group) at the 2-year follow-up (hazard ratio [95% CI], 0.62 [0.51–0.76]; P < 0.0001). A higher OS 
rate was observed in the nivolumab vs placebo group at 1 (27.3% vs 11.6%) and 2 years (10.6% vs 3.2%). The OS benefit 
was observed regardless of tumor PD-L1 expression. Among patients with a complete or partial response (CR or PR) in the 
nivolumab group, the median OS (95% CI) was 26.6 (21.65—not applicable) months; the OS rates at 1 and 2 years were 
87.1% and 61.3%, respectively. No new safety signals were identified.
Conclusions Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previ-
ously treated G/GEJ cancer. The long-term survival benefit of nivolumab was most evident in patients with a CR or PR.
Keywords Gastric cancer · Gastroesophageal junction cancer · Long-term · Nivolumab · Placebo
Introduction
Over 1,000,000 new cases of gastric/gastroesophageal junc-
tion (G/GEJ) cancer were reported in 2018 [1], and it is 
responsible for an estimated 783,000 deaths (equating to 
one in every 12 deaths) worldwide. It is the fifth most fre-
quently diagnosed cancer and the third leading cause of 
cancer death globally. The incidences of G/GEJ cancer are 
markedly higher in eastern Asia, including Japan and Korea 
[1]. Korea has the highest rates of G/GEJ worldwide in both 
sexes [1]. The cumulative risk of developing gastric can-
cer from birth to age 74 is higher in males (1.87%) than in 
females (0.79%) [1]. Age-standardized rates by sex for G/
GEJ cancers in eastern Asia in 2018 were 32.1/100,000 per-
sons in men and 13.2/100,000 persons in women.
Nivolumab, an immune checkpoint inhibitor, was evalu-
ated in the phase 3 ATT RAC TION-2 study in patients with 
G/GEJ cancer treated with ≥ 2 prior chemotherapy regimens 
[2]. This study previously reported a median overall sur-
vival (OS) of 5.26 months with nivolumab vs 4.14 months 
with placebo. The OS rates at 12 months were 26.2% and 
10.9% and the progression-free survival (PFS) rates were 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1012 0-019-01034 -7) contains 
supplementary material, which is available to authorized users.
 * Narikazu Boku 
 nboku@ncc.go.jp
Extended author information available on the last page of the article
511A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction…
1 3
7.6% and 1.5% with nivolumab and placebo, respectively 
[2]. Consequently, based on the results of ATT RAC TION-2 
[2], nivolumab is currently approved in Japan [3], South 
Korea [4], Taiwan [5], Singapore [6], and Switzerland [7] as 
a third- or later-line therapeutic option in heavily pretreated 
patients with unresectable advanced or recurrent G/GEJ can-
cer. Nivolumab is also recommended as third- or later-line 
therapy in the guidelines for treatment of gastric cancer 2018 
in Japan and Korea [8, 9].
Currently, evidence for standard-of-care in third- or 
later-line therapy for patients with advanced G/GEJ cancer 
is limited. This includes studies such as KEYNOTE-059 
[10], INTEGRATE [11], TAGS [12], JAVELIN Gastric 300 
[13], and a Chinese apatinib study [14]. Most of the studies 
do not provide evidence of long-term efficacy in patients 
with G/GEJ cancer, with the exception of the phase 2 KEY-
NOTE-059 study that evaluated the long-term efficacy and 
safety of pembrolizumab, another immune checkpoint inhib-
itor [15].
Thus, limited long-term data of immune checkpoint 
inhibitors exist in advanced G/GEJ cancer, while long-term 
survival benefits of nivolumab have been reported in other 
types of malignant diseases [16–22]. Herein, we report the 
2-year follow-up results of ATT RAC TION-2 (data cutoff, 
February 18, 2018). Because the durability of the survival 
benefits, especially in patients achieving objective tumor 
response remains unclear, we also performed an analysis of 
OS by best overall response (BOR).
Methods
Study design
ATT RAC TION-2 is a randomized, double-blind, placebo-
controlled, phase 3 study conducted at 49 sites in Japan, 
South Korea, and Taiwan. The methods have been published 
previously [2]. In brief, eligible patients were randomized 
(2:1) to receive nivolumab or placebo. Randomization was 
stratified according to country (Japan vs Korea vs Taiwan), 
number of organs with metastases (< 2 vs ≥ 2), and Eastern 
Cooperative Oncology Group (ECOG) performance status 
(0 vs 1). The protocol and its amendments were approved 
by the independent ethics committee or institutional review 
board at each study center. Written informed consent was 
provided by all patients before enrollment, and a separate 
written consent was obtained for collection of tumor tissue 
for biomarker analysis. The study was conducted in accord-
ance with the Declaration of Helsinki and the Good Clinical 
Practice guidelines developed by the International Council 
for Harmonisation of Technical Requirements for Pharma-
ceuticals for Human Use.
Patients
Patients aged 20 years or older with unresectable advanced 
or recurrent G/GEJ cancer, histologically confirmed to be 
adenocarcinoma refractory to or intolerant of standard 
therapy, were eligible for inclusion in the study. Patients 
must have received treatment with two or more lines of 
previous chemotherapy in the advanced or recurrent set-
ting, have an ECOG performance status of 0 or 1, and a life 
expectancy of at least 3 months. Patients previously treated 
with anti-programmed death-1 (PD-1), anti-programmed 
death ligand-1 (PD-L1) or anti-PD-L2, anti-CD137, or 
anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-
4) antibodies were excluded. Further details of exclusion 
criteria are mentioned in the previous publication [2].
Treatment and assessments
Patients received an intravenous infusion of nivolumab 
(3 mg/kg) or placebo every 2 weeks for 6 weeks (one treat-
ment cycle). Study treatment was continued until disease 
progression or the onset of toxicities requiring permanent 
treatment discontinuation. After initial evidence of disease 
progression, patients could continue the study treatment 
provided the following criteria were met: evidence of clin-
ical benefit, tolerance for the study drug and stable per-
formance status, treatment continuation not impacting any 
interventions required to prevent serious complications 
by disease progression, and provision of written informed 
consent to continue study treatment by the patient. The 
minimum follow-up period was defined as the time from 
randomization of the last patient to data cutoff.
The primary endpoint was OS. Secondary efficacy end-
points were PFS, objective response rate [ORR; propor-
tion of patients with confirmed complete response (CR) or 
partial response (PR)], disease control rate [proportion of 
patients with confirmed CR, PR, or stable disease (SD)], and 
BOR [CR + PR, SD, and progressive disease (PD)]. Tumor 
responses were assessed with computed tomography (CT) 
or magnetic resonance imaging (MRI) after each treatment 
cycle for first ten cycles and after every two treatment cycles 
thereafter until discontinuation of study treatment or the ini-
tiation of the poststudy treatment. Tumors were assessed 
according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) guidelines version 1.1 [23].
Adverse events (AEs) were evaluated using the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events version 4.0 [24] during treatment (+ 28 days). Inci-
dences of treatment-related adverse events (TRAEs) of spe-
cial interest (AEs of special clinical interest with a potential 
immune-related etiology) were also evaluated.
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Tumor tissue collection was not mandatory, and explora-
tory analysis of PD-L1 expression (PD-L1 positivity: 1% or 
more of tumor cells) was performed by a central laboratory 
using immunohistochemistry (28-8 pharmDx assay; Dako, 
Carpinteria, CA, USA) on the available tumor samples. 
Exploratory subanalysis of OS was performed in patients 
with CR + PR, SD, and PD.
Additionally, an exploratory landmark analysis was 
performed in patients who had SD at the first 6-week 
assessment. Patients with SD at the first 6-week assess-
ment were categorized into the following three groups 
based on the tumor growth rate at 6  weeks: group 1 
(− 30% < and ≤  − 5%), group 2 (− 5% < and <  + 5%), and 
group 3 (+ 5% ≤ and <  + 20%); OS curves were gener-
ated from 6 weeks onwards. The tumor growth rate was 
calculated as a change in tumor volume from baseline in 
the 6-week period. Since no definitive cutoff value was 
specified for this categorization, this landmark analysis was 
exploratory.
Statistical analysis
Sample size estimation has been described previously [2]. 
OS and PFS were compared between the treatment groups 
using the stratified log-rank test with a one-sided signifi-
cance level of 0.025. Hazard ratio [HR; 95% confidence 
interval (CI)] was calculated using the stratified Cox pro-
portional hazards model. The Kaplan–Meier method was 
used to estimate the median OS and median PFS, and for 
the subanalysis of OS by BOR and by tumor PD-L1 expres-
sion status. For the landmark analysis, standard OS curves 
were generated for patients found to have SD at the first 
evaluation (6 weeks), and the patients were categorized into 
three groups based on the tumor growth rate at 6 weeks. All 
analyses were performed using SAS versions 9.3 and 9.4 
(SAS Institute, Inc., Cary, NC, USA).
Results
Patient disposition and baseline characteristics
Overall, 601 patients were screened, of whom 493 
(nivolumab, 330; placebo, 163) were randomized in ATT 
RAC TION-2. The safety assessment population com-
prised 491 patients (nivolumab, 330; placebo, 161), and 
the response assessment population comprised 399 patients 
with measurable lesions (nivolumab, 268; placebo, 131; 
data cutoff, February 18, 2018). Further details of patient 
disposition have been reported previously [2]. The median 
age (interquartile range [IQR]) and proportion of men were 
62 (54–69) years and 69.4% in the nivolumab group and 61 
(53–68) years and 73% in the placebo group, respectively. 
No substantial difference was observed in the baseline 
characteristics between the nivolumab and placebo groups 
(Online Resource Table 1).
Exposure and subsequent pharmacotherapy
The median (min–max) duration of treatment was 
1.92 (0.0–28.4)  months with nivolumab and 1.05 
(0.0–29.9) months with placebo. Overall, the relative dose 
intensity of nivolumab was 90% to < 110% in 79.4% of 
patients. Details of the study drug exposure and administra-
tion are presented in Online Resource Table 2.
At data cutoff, study treatment was permanently discon-
tinued in 322 patients (97.6%) in the nivolumab group and in 
161 patients (98.8%) in the placebo group. Reasons for treat-
ment discontinuation (nivolumab vs placebo, respectively) 
were as follows: disease progression (237 [71.8%] vs 109 
[67.7%]), worsening of clinical symptoms judged as PD (59 
[17.9%] vs 39 [24.2%]), onset of grade ≥ 2 interstitial lung 
disease (5 [1.5%] vs 0 [0%]), physician discretion (13 [3.9%] 
vs 3 [1.9%]), treatment withheld longer than 6 weeks due to 
AEs (7 [2.1%] vs 1 [0.6%]), and other reasons (27 [8.2%] 
vs 19 [11.8%]).
Following study treatment discontinuation, 53.6% 
(177/330) and 47.2% (77/163) of patients in the nivolumab 
and placebo groups, respectively, received subsequent anti-
cancer treatment (pharmacotherapy, 41.5% [137/330] and 
35% [57/163]; surgery, 20.9% [69/330] and 17.2% [28/163]; 
radiotherapy, 8.5% [28/330] and 10.4% [17/163]; Online 
Resource Table 3). Among all patients, 109 (33%) patients 
in the nivolumab group and 37 (23%) patients in the placebo 
group continuously received the study treatment after being 
judged as having PD as per RECIST version 1.1. In total, 
six (1.8%) patients in the nivolumab group and two (1.2%) 
patients in the placebo group received immune checkpoint 
inhibitors as subsequent therapy.
Efficacy
The median OS (95% CI) in the nivolumab vs placebo group 
was 5.26 (4.60–6.37) vs 4.14 (3.42–4.86) months at the 
2-year follow-up. The OS rate was longer in the nivolumab 
group than in the placebo group throughout the study 
period [2]. The risk of death was significantly lower in the 
nivolumab group than in the placebo group (HR [95% CI], 
0.62 [0.51–0.76]; P < 0.0001; Fig. 1a). A higher OS rate 
was also observed in the nivolumab group compared with 
the placebo group at 1 year (27.3% vs 11.6%) and 2 years 
(10.6% vs 3.2%).
The median PFS (95% CI) in the nivolumab group com-
pared with the placebo group was 1.61 (1.54–2.30) vs 1.45 
(1.45–1.54) months at the 2-year follow-up. The PFS rate 
was higher in the nivolumab group than in the placebo group 
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after approximately 2 months of treatment initiation through-
out the study period [2]. The risk of disease progression was 
lower in the nivolumab than in the placebo group (HR [95% 
CI], 0.60 [0.49–0.75]; P < 0.0001; Fig. 1b). The PFS rate at 
1 year was higher in the nivolumab group compared with 
the placebo group (9.3% vs 1.5%); at 2 years, the PFS rate 
was 3.8% in the nivolumab group, and disease progression 
was reported in all patients in the placebo group. Subgroup 
analyses of OS according to baseline demographics and 
disease characteristics consistently favored nivolumab over 
placebo (Online Resource Fig. 1).
BOR
The ORR was greater in the nivolumab group than in the 
placebo group, with a CR or PR observed in 32 patients 
(11.9%; CR, 3 [1.1%] and PR, 29 [10.8%]) compared with no 
patients, respectively, at the 2-year follow-up (median [IQR], 
27.2 [25.2–29.9] months). Of note, no CRs and 30 PRs had 
been observed at the initial follow-up (median, 8.9 months; 
ORR: nivolumab, 11.2%; placebo, 0%) [2]. Taken together, 
three cases of PR at the 1-year follow-up transitioned to 
CR at the 2-year follow-up. BOR is described in Table 1. 
All three patients in the nivolumab group were evaluated as 
CR at assessment of week 66 with 11 cycles of nivolumab 
after they had shown PR at the 1-year follow-up. All three 
patients with CR at the 2-year follow-up had a baseline 
ECOG performance status of 1 with liver or lung metastasis 
and extensive lymph nodal, including supraclavicular node, 
metastasis. The details of the three patients with CR are 
shown in Online Resource Table 4.
Subanalysis of OS by BOR
Among patients with a CR or PR in the nivolumab 
group, the median (95% CI) OS was 26.6 (21.65—not 
applicable) months; the OS rates at 1 and 2 years were 
87.1% and 61.3%, respectively. No patient in the placebo 
group had a CR or PR (Fig. 2a). Results of the suba-
nalysis by BOR showed that among patients with SD, a 
Fig. 1  Kaplan–Meier plot of OS 
(a) and PFS (b) after 2 years of 
follow-up. Marks on the curve 
indicate patients who were cen-
sored. CI confidence interval, 
HR hazard ratio, OS overall 
survival, PFS progression-free 
survival
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Table 1  Best overall response in 
the overall population
CR complete response, NE not evaluable, PD progressive disease, PR partial response, SD stable disease
n (%) Overall population
Nivolumab (n = 268) Placebo (n = 131)
Best overall response
 CR 3 (1.1) 0
 PR 29 (10.8) 0
 SD 76 (28.4) 33 (25.2)
 PD 124 (46.3) 79 (60.3)
 NE 36 (13.4) 19 (14.5)
Objective response rate (CR or PR) 32 (11.9) 0
Disease control rate (CR, PR, or SD) 108 (40.3) 33 (25.2)
Fig. 2  Subanalysis of OS by 
BOR among patients with 
CR + PR (a), SD (b), and PD 
(c). Marks on the curve indicate 
patients who were censored. 
BOR best overall response, 
CI confidence interval, CR 
complete response, HR hazard 
ratio, NA not applicable, OS 
overall survival, PD progressive 
disease, PR partial response, SD 
stable disease
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marginally longer OS was also observed (median [95% 
CI]: nivolumab, 8.87 [7.95–11.33] months; placebo, 7.62 
[5.13–9.86]  months; HR [95% CI], 0.80 [0.52–1.23]; 
Fig. 2b). The survival curves for patients with PD over-
lapped within 1 year, while five patients in the nivolumab 
group survived longer than 2 years (median [95% CI] 
OS: nivolumab, 3.84 [3.42–4.21] months; placebo, 3.75 
[2.96–4.37]  months; HR [95% CI], 0.83 [0.62–1.12]; 
Fig. 2c). All of these five patients received post-progres-
sion anticancer therapies, and three of them continued 
nivolumab after disease progression. One patient showed 
some tumor shrinkage beyond PD.
Exploratory analysis
Exploratory analysis based on PD-L1 expression sta-
tus showed that median (95% CI) OS in patients with 
PD-L1-positive tumors was 5.22 (2.79–9.36)  months 
in the nivolumab group and 3.83 (0.79–4.96) months 
in the placebo group (HR [95% CI], 0.75 [0.32–1.72]; 
Online Resource Fig.  2a). In patients with PD-
L1-negative tumors, median (95% CI) OS was 6.05 
(4.83–8.61) months in the nivolumab group and 4.19 
(3.02–6.93) months in the placebo group (HR [95% CI], 
0.70 [0.50–0.99]; Online Resource Fig. 2b). The OS ben-
efit was observed regardless of PD-L1 expression status 
as reported previously [2].
Among patients in whom response could be evaluated, 
the exploratory landmark analysis showed that in patients 
with SD at the first 6-week assessment, difference in the 
median OS between the nivolumab and placebo groups was 
8.81, 3.55, and 3.15 months in the tumor growth rate group 
1 (− 30% < and ≤  − 5%), group 2 (− 5% < and <  + 5%), and 
group 3 (+ 5% ≤ and <  + 20%), respectively. The OS rate 
and curves in the nivolumab group were slightly better than 
those in the placebo group across the three tumor growth 
rate groups (Online Resource Fig. 3).
Safety
Safety analyses were performed in 330 patients in the 
nivolumab group and 161 patients in the placebo group 
who received one or more doses of nivolumab. All-cause 
AEs of any grade were reported in 301 (91.2%) of 330 
patients in the nivolumab group and 135 (83.9%) of 161 
patients in the placebo group. TRAEs of any grade were 
reported in 142 (43.0%) patients in the nivolumab group 
and 43 (26.7%) patients in the placebo group, including 39 
(11.8%) and seven (4.3%) patients with grade 3–4 TRAEs, 
respectively. Serious TRAEs were reported in 38 (11.5%) 
of 330 patients in the nivolumab group and eight (5.0%) of 
161 patients in the placebo group. Most patients experienced 
onset of TRAEs of special interest within 3 months of start-
ing nivolumab: skin, gastrointestinal, hepatic, and endocrine 
TRAEs were most commonly experienced at 3 months and 
tended to abate over time. The incidence rates of TRAEs of 
special interest were comparable at 6 months, 1 year, and 
2 years. No major late-onset TRAEs were observed (Fig. 3). 
Among TRAEs of special interest, one additional case each 
of maculopapular rash and pneumonitis was observed during 
the additional follow-up period, compared with the previous 
publication [2] (Online Resource Table 5).
Discussion
Large-scale clinical trials of third-line treatment for 
advanced/recurrent G/GEJ cancer are limited. The results 
of this long-term follow-up of ATT RAC TION-2 [2] dem-
onstrated that compared with placebo, nivolumab sig-
nificantly prolonged the OS (5.26 vs 4.14 months), with 
numerically higher OS (10.6% vs 3.2%) and PFS rates 
(3.8% vs 0%) at 2  years in patients with unresectable 
advanced or recurrent G/GEJ cancer after two or more 
prior chemotherapy regimens. While the OS rates were 
higher in the nivolumab group than in the placebo group 
Fig. 3  Emergence of treatment-
related AEs (any grade) of 
special interest over time. AE 
adverse event
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throughout the study period, higher PFS rates favoring 
nivolumab became evident after approximately 2 months 
of treatment initiation [2].
Furthermore, treatment discontinuation rate due to AEs 
was low, and no new safety signals were identified compared 
with previous reports in patients with various cancer types 
[2, 16, 19, 21, 25–28]. Most patients experienced their first 
onset of TRAE of special interest (immune-related) within 
3 months of starting nivolumab. Thereafter, the incidence of 
TRAEs of special interest was low and tended to abate over 
time, suggesting a favorable long-term tolerability profile 
for continued nivolumab therapy. However, monitoring is 
recommended to identify any potential late-onset AEs.
In the nivolumab group, there were 32 patients with 
CR or PR. In the OS subanalysis by BOR, a median OS of 
26.6 months was observed in these patients. The number 
of patients with CR increased from zero to three during the 
2-year follow-up. The three patients with CR did not dem-
onstrate any specific background characteristics.
The results showed that the survival benefit over the 
2-year follow-up period was observed regardless of PD-L1 
expression status, as reported previously [2]. Limitations of 
this study are that the exploratory analysis of tumor PD-L1 
expression status was performed in a limited number of 
patients, and PD-L1 expression was analyzed only in tumor 
cells.
A total of 76 patients (28.4%) on nivolumab had SD. 
Patients with SD at 6 weeks had a range of tumor growth 
rate from − 30 to + 20%, meaning either a slight decrease 
or a slight increase. We performed an exploratory analy-
sis that assessed OS among SD patients by subgrouping 
them based on the tumor growth rate at the first assessment 
(6 weeks; RECIST criteria) to examine whether or not the 
continued use of nivolumab could provide clinical benefit 
to SD patients even after a slight increase in tumor size. 
When categorized by three tumor growth rate groups (− 3
0% < and ≤  − 5%; − 5% < and <  + 5%; + 5% ≤ and <  + 20%) 
in these patients with SD at 6 weeks, the OS rate/curves in 
the nivolumab group were higher than those in the placebo 
group across the three tumor growth rate groups. Compar-
ing OS in the subset showing SD at 6 weeks might provide 
further insights into the efficacy of nivolumab. Patients 
with SD in the placebo group had more indolent and slow-
growing tumors compared with patients with PD, but some 
of the patients with SD in the nivolumab group might have 
had aggressive tumors whose growth could be inhibited by 
nivolumab. Furthermore, in the phase III trial of nivolumab 
in non-small cell lung cancer, discontinuation of nivolumab 
after disease control for 1 year resulted in poor prognosis 
compared with its continuation [29]. It is suggested that 
continuous therapy with nivolumab could still be a viable 
treatment option even after a small increase in tumor size 
within SD.
All five of the patients with PD at initial response assess-
ment who survived longer than 2 years received post-pro-
gression therapy, and three of them continued nivolumab 
beyond PD. Only one patient showed tumor shrinkage with 
nivolumab beyond PD. While this study allowed continu-
ation of nivolumab beyond PD conditionally, the clinical 
significance of this treatment is not clear.
Overall, the results of OS by BOR should be interpreted 
with caution because clinical significance of continuing 
nivolumab should be confirmed in a randomized trial. Fur-
thermore, other prognostic factors, including natural tumor 
growth kinetics (i.e., slow tumor progression with good 
prognosis), may have influenced the outcome in patients 
with SD.
Conclusions
The efficacy of nivolumab was similar to and sustained from 
the 1-year follow-up as demonstrated by continued clinically 
meaningful improvements in OS and PFS at the 2-year fol-
low-up compared with placebo. The long-term survival ben-
efit of nivolumab was most evident in patients with CR or 
PR than in those with SD or PD. Even among patients with 
SD categorized by tumor growth rate, nivolumab offered a 
longer median OS than placebo, suggesting that nivolumab 
can be continued even after a small increase in tumor size 
within SD. However, these observations will need to be vali-
dated in future studies by evaluating the use of nivolumab in 
beyond-PD cases. The safety profile was similar to that at the 
1-year follow-up, and no major late-onset TRAEs of special 
interest were observed; however, continual monitoring of 
AEs was necessary.
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